Kyprolis
Evidence Grade A — Regulatory approved. 1780 published studies. 211 registered clinical trials.
Loading...
Carfilzomib (sold as Kyprolis) is an intravenous cancer treatment for multiple myeloma that has come back after previous therapy. Like bortezomib, it works by blocking the cell's protein recycling system, but carfilzomib binds permanently rather than temporarily, which may contribute to its stronger anti-cancer effect in some settings.
1,780 published studies: 1343 human, 47 animal, 220 in-vitro, 420 reviews
Carfilzomib is marketed as Kyprolis (approved July 2012) for relapsed or refractory multiple myeloma. It is administered intravenously on a twice-weekly schedule in combination with other agents.
In the ENDEAVOR trial, the carfilzomib-dexamethasone combination nearly doubled progression-free survival compared to bortezomib-dexamethasone (18.7 versus 9.4 months). The ASPIRE trial showed that adding carfilzomib to lenalidomide-dexamethasone extended overall survival by approximately 8 months. Cardiovascular toxicity (heart failure, hypertension) is the most significant side effect and requires cardiac monitoring. The intravenous-only administration and twice-weekly schedule are practical limitations compared to oral proteasome inhibitors now in development.
Cells contain a structure called the proteasome that breaks down old, damaged, or excess proteins — acting as the cell's recycling system. Myeloma cells produce enormous quantities of antibody proteins and are especially dependent on this system to avoid being overwhelmed by protein waste. Carfilzomib permanently disables the proteasome's main cutting site by forming an irreversible chemical bond, causing toxic proteins to accumulate until the cell self-destructs. Its irreversible binding distinguishes it from the older bortezomib, which binds reversibly.
Carfilzomib's evidence is strong. The ENDEAVOR trial showed that carfilzomib nearly doubled the time before disease worsened compared to bortezomib (18.7 versus 9.4 months) in patients with relapsed myeloma. The ASPIRE trial demonstrated an overall survival benefit of approximately 8 months when carfilzomib was added to a standard two-drug regimen. The most significant concern is cardiovascular toxicity — heart failure and hypertension occur at clinically meaningful rates, requiring cardiac monitoring during treatment. The grade 3 or higher adverse event rate is around 80%, reflecting that this is an intensive cancer treatment. The twice-weekly IV schedule is also a practical burden for patients. Research continues into frontline use and subcutaneous formulation development that could ease the administration burden.
Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease
Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment
Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse
Treatment of Antibody-Mediated Rejection (ABMR) With CarBel
FDA ORIG 1
FDA SUPPL 1
FDA SUPPL 2
FDA SUPPL 3
FDA SUPPL 4
FDA SUPPL 5
FDA SUPPL 8
FDA SUPPL 6
FDA SUPPL 7
FDA SUPPL 9
EMA Marketing Authorisation
FDA SUPPL 10
Health Canada Market Authorisation
FDA SUPPL 11
FDA SUPPL 12
FDA SUPPL 13
FDA SUPPL 15
FDA SUPPL 14
FDA SUPPL 16
FDA SUPPL 17
FDA SUPPL 19
FDA SUPPL 21
FDA SUPPL 25
FDA SUPPL 27
FDA SUPPL 29
FDA SUPPL 30
FDA SUPPL 32
FDA SUPPL 33
FDA SUPPL 34
FDA SUPPL 36
Corticotropin is marketed as H.P. Acthar Gel (currently ANI Pharmaceuticals). It carries approximately 19 FDA-labelled indications including infantile spasms (its strongest evidence base), nephrotic syndrome, multiple sclerosis relapses, and rheumatic disorders. Acthar Gel has been at the centre of major pricing and legal controversies. The price rose from approximately $40 per vial in 2001 to over $40,000, driven by successive acquisitions and orphan-like positioning despite broad labelling. The former manufacturer Mallinckrodt agreed to a $260 million settlement over antitrust concerns. Clinically, the strongest evidence supports its use in infantile spasms, where it is considered a first-line treatment. For most other indications, debate continues over whether it offers meaningful advantages over far less expensive oral corticosteroids.
Enfuvirtide is marketed as Fuzeon (approved March 2003). It requires twice-daily subcutaneous injections, and injection-site reactions occur in nearly all patients (98%). In clinical trials (TORO-1 and TORO-2), enfuvirtide combined with an optimised background regimen achieved significantly greater viral suppression than background regimen alone in treatment-experienced patients. Enfuvirtide represented a major advance when HIV drug resistance was a more pressing clinical challenge, but its use has declined substantially with the arrival of more convenient oral antiretrovirals. The twice-daily injection burden, injection-site reactions, high cost, and complex manufacturing (it is one of the largest synthetic peptides manufactured at scale) have limited its role to a last-resort option for patients with highly resistant HIV.
Vancomycin is marketed as Vancocin and Firvanq (approved 1958, with oral solution Firvanq approved 2018). It is the standard treatment for serious MRSA infections (bloodstream infections, endocarditis, pneumonia, bone infections) and is first-line for severe C. difficile colitis. Vancomycin requires therapeutic drug monitoring — blood levels must be checked regularly to ensure the dose is effective without causing kidney damage or hearing loss. The rise of vancomycin-resistant enterococci (VRE) and occasional vancomycin-intermediate S. aureus (VISA) strains represent ongoing challenges. Despite being nearly 70 years old, vancomycin remains irreplaceable for many serious infections, though newer alternatives like daptomycin and the lipoglycopeptides offer advantages in specific settings.
